Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism

The calcimimetic agent cinacalcet is effective for the management of secondary hyperparathyroidism (SHPT) in dialysis patients. Changes to reimbursement of cinacalcet in Australia provided an opportunity to as...

Source: BMC Nephrology - May 15, 2018 Category: Urology & Nephrology Authors: Irene Ruderman, Edward R. Smith, Nigel D. Toussaint, Tim D. Hewitson and Stephen G. Holt Tags: Research article Source Type: research